Table 6.

Effect of clinical variables on serum infliximab levels after switch to SC CT-P13.

Variable	Regression co-efficient	95% CI	p-value
Clinically active disease	-0.325	-0.938, 0.288	0.294
CRP >5mg/L	0.480	-0.347, 1.306	0.252
FC >250 µg/g	-0.115	-0.679, 0.449	0.686
BMI	-0.030	-0.072, 0.012	0.162
Dosing regimen [weekly/EOW]	0.316	-0.183, 0.815	0.211
Concomitant immunomodulators	0.045	-0.399, 0.490	0.840
Antibodies to infliximab	-13.369	-15.405, -11.333	<0.001

SC, subcutaneous; CI, confidence interval; CRP, C-reactive protein; FC, faecal calprotectin; BMI, body mass index; EOW, every other week.